Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494068 | 1.00 | PYGB (0.47) | PYGBGAACA12CA1CA2 | |
| SCHEMBL7123019 | 0.82 | MAPK1 (0.57) | PYGBGAACA1CA2CA9 | |
| SCHEMBL5498712 | 0.82 | MAPK1 (0.57) | PYGBGAACA1CA2CA9 | |
| SCHEMBL5498717 | 0.82 | MAPK1 (0.57) | PYGBGAACA1CA2CA9 | |
| SCHEMBL5490050 | 0.82 | PYGB (0.44) | PYGBGAACA12CA1CA2 | |
| SCHEMBL7551748 | 0.80 | PYGB (0.54) | PYGBGAACA12CA1CA2 | |
| SCHEMBL8584488 | 0.78 | PYGB (0.49) | PYGBGAAEPHX2 | |
| SCHEMBL8587178 | 0.78 | PYGB (0.49) | PYGBGAAEPHX2 | |
| SCHEMBL10528729 | 0.77 | CETP (0.44) | PYGBCETPMAPK1 | |
| SCHEMBL10529704 | 0.77 | CETP (0.44) | PYGBCETPMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312194-B2 | Delivery systems | ALCHEMIA PTY. LTD. (AU) | 2007-12-25 | — | — | US | disclosed |
| US-20040176281-A1 | Delivery systems | ALCHEMIA LIMITED (AU) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176281-A1 | Delivery systems | MTX2, SGMS2, SGMS1 | PYGB 3922/4885GAA 229/4885CA12 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.